Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: A review

World Journal of Gastroenterology

Volumn 21, Issue 4, 2015, Pages 1081-1090

  Keshteli, Ammar Hassanzadeh ^a   Baracos, Vickie E ^a   Madsen, Karen L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Colorectal cancer; Hyperhomocysteinemia; Inflammatory bowel disease

Indexed keywords

DNA; HOMOCYSTEINE; OXYGEN RADICAL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

AMINO ACID METABOLISM; ANEUPLOIDY; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLON DISEASE; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DNA DAMAGE; ENDOTHELIUM INJURY; FAMILY HISTORY; FIRST DEGREE RELATIVE; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENOME IMPRINTING; HETEROZYGOSITY LOSS; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); MITOTIC RECOMBINATION; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SPORADIC COLORECTAL CANCER; ULCERATIVE COLITIS; UPREGULATION; BLOOD; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; INFLAMMATORY BOWEL DISEASES; METABOLISM; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84921789418     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i4.1081     Document Type: Review

References (70)

1. Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease-epidemiology and treatment. Aliment Pharmacol Ther 2009; 30: 99-112 [PMID: 19438426 DOI: 10.1111/j.1365-2036.2009.04035.x]
2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12 Suppl 1: S3-S9 [PMID: 16378007 DOI: 10.1097/01.MIB.0000195385.19268.68]
3. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res 2011; 185: 99-115 [PMID: 21822822 DOI: 10.1007/978-3-642-03503-6-6]
4. Basseri RJ, Basseri B, Papadakis KA. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011; 5: 59-66 [PMID: 21309672 DOI: 10.1586/egh.10.77]
5. Schalinske KL, Smazal AL. Homocysteine imbalance: a pathological metabolic marker. Adv Nutr 2012; 3: 755-762 [PMID: 23153729 DOI: 10.3945/an.112.002758]
6. Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, Ferekidis E, Kandiloros D. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res 2006; 26: 2345-2348 [PMID: 16821614]
7. Plazar N, Jurdana M. Hyperhomocysteinemia and the role of B vitamins in cancer. Radiol Oncol 2010; 44: 79-85 [PMID: 22933895 DOI: 10.2478/v10019-010-0022-z]
8. Kedzierska M, Malinowska J, Glowacki R, Olas B, Bald E, Jeziorski A, Piekarski J. The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients. Mol Cell Biochem 2011; 355: 193-199 [PMID: 21533764 DOI: 10.1007/s11010-011-0854-x]
9. Wang L, Ke Q, Chen W, Wang J, Tan Y, Zhou Y, Hua Z, Ding W, Niu J, Shen J, Zhang Z, Wang X, Xu Y, Shen H. Polymorphisms of MTHFD, plasma homocysteine levels, and risk of gastric cancer in a high-risk Chinese population. Clin Cancer Res 2007; 13: 2526-2532 [PMID: 17438114 DOI: 10.1158/1078-0432.CCR-06-2293]
10. Lin J, Lee IM, Song Y, Cook NR, Selhub J, Manson JE, Buring JE, Zhang SM. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res 2010; 70: 2397-2405 [PMID: 20197471 DOI: 10.1158/0008-5472.CAN-09-3648]
11. Nacci A, Dallan I, Bruschini L, Traino AC, Panicucci E, Bruschini P, Mancini V, Rognini F, Fattori B. Plasma homocysteine, folate, and vitamin B12 levels in patients with laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 1328-1333 [PMID: 19075131 DOI: 10.1001/archotol.134.12.1328]
12. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]
13. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012; 3: 107 [PMID: 22586430 DOI: 10.3389/fimmu.2012.00107]
14. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000; 11: 191-196 [PMID: 10967506 DOI: 10.1016/S0953-6205(00)00090-X]
15. Fedorak RN, Wong K, Bridges R. Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 2010; 24: 651-655 [PMID: 21157579]
16. Goh K, Xiao SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis 2009; 10: 1-6 [PMID: 19236540 DOI: 10.1111/j.1751-2980.2008.00355.x]
17. Qin X. Etiology of inflammatory bowel disease: a unified hypothesis. World J Gastroenterol 2012; 18: 1708-1722 [PMID: 22553395 DOI: 10.3748/wjg.v18.i15.1708]
18. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389 [PMID: 22609382 DOI: 10.1053/j.gastro.2012.04.054]
19. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 2012; 18: 3839-3848 [PMID: 22876036 DOI: 10.3748/wjg.v18.i29.3839]
20. Andersen V, Halfvarson J, Vogel U. Colorectal cancer in patients with inflammatory bowel disease: can we predict risk? World J Gastroenterol 2012; 18: 4091-4094 [PMID: 22919240 DOI: 10.3748/wjg.v18.i31.4091]
21. Guagnozzi D, Lucendo AJ. Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? World J Gastrointest Endosc 2012; 4: 108-116 [PMID: 22523611 DOI: 10.4253/wjge.v4.i4.108]
22. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]
23. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut 2009; 58: 1226-1233 [PMID: 19251712 DOI: 10.1136/gut.2008.166686]
24. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-246 [PMID: 10448523 DOI: 10.1146/annurev.nutr.19.1.217]
25. Selhub J. Public health significance of elevated homocysteine. Food Nutr Bull 2008; 29: S116-S125 [PMID: 18709886]
26. Battistelli S, Vittoria A, Stefanoni M, Bing C, Roviello F. Total plasma homocysteine and methylenetetrahydrofolate reductase C677T polymorphism in patients with colorectal carcinoma. World J Gastroenterol 2006; 12: 6128-6132 [PMID: 17036383]
27. Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors 2010; 36: 19-24 [PMID: 20091801]
28. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta 2002; 322: 21-28 [PMID: 12104077 DOI: 10.1016/S0009-8981(02)00174-2]
29. Phelip JM, Ducros V, Faucheron JL, Flourie B, Roblin X. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 242-248 [PMID: 17941074 DOI: 10.1002/ibd.20309]
30. Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Med Hypotheses 2011; 77: 1088-1093 [PMID: 21963358 DOI: 10.1016/j.mehy.2011.09.009]
31. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996; 366: 23-44 [PMID: 8921985 DOI: 10.1016/S0165-1110(96)90005-6]
32. Chiang FF, Wang HM, Lan YC, Yang MH, Huang SC, Huang YC. High homocysteine is associated with increased risk of colorectal cancer independently of oxidative stress and antioxidant capacities. Clin Nutr 2014; 33: 1054-1060 [PMID: 24280101 DOI: 10.1016/j.clnu.2013.11.007]
33. Ferroni P, Palmirotta R, Martini F, Riondino S, Savonarola A, Spila A, Ciatti F, Sini V, Mariotti S, Del Monte G, Roselli M, Guadagni F. Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res 2009; 29: 4131-4138 [PMID: 19846961]
34. Lambert D, Benhayoun S, Adjalla C, Gelot MA, Renkes P, Felden F, Gerard P, Belleville F, Gaucher P, Guéant JL, Nicolas JP. Crohn' s disease and vitamin B12 metabolism. Dig Dis Sci 1996; 41: 1417-1422 [PMID: 8689919 DOI: 10.1007/BF02088567]
35. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011; 34: 1173-1184 [PMID: 21967576 DOI: 10.1111/j.1365-2036.2011.04864.x]
36. Kallel L, Feki M, Sekri W, Segheir L, Fekih M, Boubaker J, Kaabachi N, Filali A. Prevalence and risk factors of hyperhomocysteinemia in Tunisian patients with Crohn's disease. J Crohns Colitis 2011; 5: 110-114 [PMID: 21453879 DOI: 10.1016/j.crohns.2010.10.010]
37. Erzin Y, Uzun H, Celik AF, Aydin S, Dirican A, Uzunismail H. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications. J Clin Gastroenterol 2008; 42: 481-486 [PMID: 18344891 DOI: 10.1097/MCG.0b013e318046eab0]
38. Mahmood A, Needham J, Prosser J, Mainwaring J, Trebble T, Mahy G, Ramage J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005; 17: 739-744 [PMID: 15947551 DOI: 10.1097/00042737-200507000-00008]
39. Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, Meucci G, Spina L, de Franchis R. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98: 112-117 [PMID: 12526945 DOI: 10.1111/j.1572-0241.2003.07160.x]
40. Zintzaras E. Genetic variants of homocysteine/folate metabolism pathway and risk of inflammatory bowel disease: a synopsis and meta-analysis of genetic association studies. Biomarkers 2010; 15: 69-79 [PMID: 20085490 DOI: 10.3109/13547500903297184]
41. Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96: 2143-2149 [PMID: 11467646 DOI: 10.1111/j.1572-0241.2001.03950.x]
42. Akoglu B, Milovic V, Caspary WF, Faust D. Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate. Eur J Nutr 2004; 43: 93-99 [PMID: 15083316 DOI: 10.1007/s00394-004-0446-6]
43. Kato I, Dnistrian AM, Schwartz M, Toniolo P, Koenig K, Shore RE, Akhmedkhanov A, Zeleniuch-Jacquotte A, Riboli E. Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer 1999; 79: 1917-1922 [PMID: 10206314 DOI: 10.1038/sj.bjc.6690305]
44. Ferroni P, Riondino S, Vazzana N, Santoro N, Guadagni F, Davì G. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost 2012; 108: 1109-1123 [PMID: 23014768 DOI: 10.1160/TH12-08-0550]
45. Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 2002; 50: 520-524 [PMID: 11889073 DOI: 10.1136/gut.50.4.520]
46. Delgado-Plasencia L, Medina-Arana V, Bravo-Gutiérrez A, Pérez-Palma J, Álvarez-Argüelles H, Salido-Ruiz E, Fernández-Peralta AM, González-Aguilera JJ. Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability. Int J Colorectal Dis 2013; 28: 1187-1193 [PMID: 23422951 DOI: 10.1007/s00384-013-1644-6]
47. Zhao M, Li X, Xing C, Zhou B. Association of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms with colorectal cancer risk: A meta-analysis. Biomed Rep 2013; 1: 781-791 [PMID: 24649029 DOI: 10.3892/br.2013.134]
48. Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Stenling R, Riboli E, Winkvist A, Palmqvist R. Low folate levels may protect against colorectal cancer. Gut 2006; 55: 1461-1466 [PMID: 16638790 DOI: 10.1136/gut.2005.085480]
49. Kaji E, Kato J, Saito S, Harada K, Kuwaki K, Tatsukawa M, Morikawa T, Hiraoka S, Matsushima H, Yamamoto K. Serum folate and homocysteine levels are associated with colon tumorigenesis in end-stage renal disease patients. Nutr Cancer 2011; 63: 202-211 [PMID: 21264789 DOI: 10.1080/01635581.2011.523501]
50. Al-Ghnaniem R, Peters J, Foresti R, Heaton N, Pufulete M. Methylation of estrogen receptor alpha and mutL homolog 1 in normal colonic mucosa: association with folate and vitamin B-12 status in subjects with and without colorectal neoplasia. Am J Clin Nutr 2007; 86: 1064-1072 [PMID: 17921385]
51. Yin G, Ming H, Zheng X, Xuan Y, Liang J, Jin X. Methylenetetrahydrofolate reductase C677T gene polymorphism and colorectal cancer risk: A case-control study. Oncol Lett 2012; 4: 365-369 [PMID: 22844384]
52. Chandy S, Sadananda Adiga MN, Ramaswamy G, Ramachandra C, Krishnamoorthy L. Effect of Vitamin B(12) and Folate on Homocysteine levels in colorectal cancer. Indian J Clin Biochem 2008; 23: 258-261 [PMID: 23105766 DOI: 10.1007/s12291-008-0058-7]
53. Kim YI, Fawaz K, Knox T, Lee YM, Norton R, Arora S, Paiva L, Mason JB. Colonic mucosal concentrations of folate correlate well with blood measurements of folate status in persons with colorectal polyps. Am J Clin Nutr 1998; 68: 866-872 [PMID: 9771864]
54. Lim YJ, Kim JH, Park SK, Son HJ, Kim JJ, Kim YH. Hyperhomocysteinemia is a risk factor for colorectal adenoma in women. J Clin Biochem Nutr 2012; 51: 132-135 [PMID: 22962532 DOI: 10.3164/jcbn.D-11-00025]
55. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C-& gt; T and methionine synthase 2756A-& gt; G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 2004; 13: 2175-2180 [PMID: 15598777]
56. Le Marchand L, White KK, Nomura AM, Wilkens LR, Selhub JS, Tiirikainen M, Goodman MT, Murphy SP, Henderson BE, Kolonel LN. Plasma levels of B vitamins and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2195-2201 [PMID: 19661077 DOI: 10.1158/1055-9965.EPI-09-0141]
57. Weinstein SJ, Albanes D, Selhub J, Graubard B, Lim U, Taylor PR, Virtamo J, Stolzenberg-Solomon R. One-carbon metabolism biomarkers and risk of colon and rectal cancers. Cancer Epidemiol Biomarkers Prev 2008; 17: 3233-3240 [PMID: 18990766 DOI: 10.1158/1055-9965.EPI-08-0459]
58. Miller JW, Beresford SA, Neuhouser ML, Cheng TY, Song X, Brown EC, Zheng Y, Rodriguez B, Green R, Ulrich CM. Homocysteine, cysteine, and risk of incident colorectal cancer in the Women's Health Initiative observational cohort. Am J Clin Nutr 2013; 97: 827-834 [PMID: 23426034 DOI: 10.3945/ajcn.112.049932]
59. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618 [PMID: 15659508 DOI: 10.1200/JCO.2005.01.086]
60. Jensen LH, Lindebjerg J, Crüger DG, Brandslund I, Jakobsen A, Kolvraa S, Nielsen JN. Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer. Cancer Invest 2008; 26: 583-589 [PMID: 18584349 DOI: 10.1080/07357900801970992]
61. Phelip JM, Roblin X. Type 2 diabetes mellitus and colorectal cancer risk: is homocysteine the missing link? Am J Gastroenterol 2007; 102: 466-467 [PMID: 17311671 DOI: 10.1111/j.1572-0241.2006.00904-17.x]
62. Martínez ME, Giovannucci E, Jiang R, Henning SM, Jacobs ET, Thompson P, Smith-Warner SA, Alberts DS. Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. Int J Cancer 2006; 119: 1440-1446 [PMID: 16615116 DOI: 10.1002/ijc.21978]
63. Serfaty L, Bissonnette M, Poupon R. Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol Clin Biol 2010; 34: 516-522 [PMID: 20609543 DOI: 10.1016/j.gcb.2010.05.005]
64. Martínez ME, Henning SM, Alberts DS. Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. Am J Clin Nutr 2004; 79: 691-697 [PMID: 15051616]
65. Bobe G, Murphy G, Rogers CJ, Hance KW, Albert PS, Laiyemo AO, Sansbury LB, Lanza E, Schatzkin A, Cross AJ. Serum adiponectin, leptin, C-peptide, homocysteine, and colorectal adenoma recurrence in the Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 1441-1452 [PMID: 20501764 DOI: 10.1158/1055-9965.EPI-09-1082]
66. Levine AJ, Grau MV, Mott LA, Ueland PM, Baron JA. Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. Cancer Epidemiol Biomarkers Prev 2010; 19: 2541-2548 [PMID: 20841390 DOI: 10.1158/1055-9965.EPI-10-0536]
67. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993; 119: 549-554 [PMID: 8392076 DOI: 10.1007/BF01686465]
68. Biasco G, Di Marco MC. Folate and prevention of colorectal cancer in ulcerative colitis. Eur J Cancer Prev 2005; 14: 395-398 [PMID: 16030431 DOI: 10.1097/00008469-200508000-00013]
69. Tang J, Sharif O, Pai C, Silverman AL. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 2010; 55: 1696-1703 [PMID: 19705280 DOI: 10.1007/s10620-009-0942-x]
70. Velayos F. Managing risks of neoplasia in inflammatory bowel disease. Curr Gastroenterol Rep 2012; 14: 174-180 [PMID: 22359106 DOI: 10.1007/s11894-012-0247-7]